- Investing Ideas
- Swiss Transformative Artificial intelligence (AI) Healthcare Stocks
Swiss Transformative Artificial intelligence (AI) Healthcare Stocks
Results
6
Artificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research. AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription. It powers telemedicine, monitors chronic conditions in real-time, and speeds up drug discovery by analyzing vast datasets for insights into complex diseases. Despite challenges like data privacy, bias, and integration costs, AI’s ability to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery and outcomes.
6 companies
Cosmo
Market Cap: CHF 1.2b
A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
COPN
CHF 71.90
7D
-10.6%
1Y
31.0%
Straumann Holding
Market Cap: CHF 15.0b
Provides tooth replacement and orthodontic solutions in Switzerland, the United States, China, Germany, Brazil, Japan, France, and internationally.
STMN
CHF 93.84
7D
3.1%
1Y
-11.9%
Tecan Group
Market Cap: CHF 2.0b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 156.90
7D
4.2%
1Y
-2.3%
Sonova Holding
Market Cap: CHF 12.1b
Manufactures and sells hearing care solutions for children and adults in Switzerland, the United States, rest of the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
SOON
CHF 203.80
7D
-3.0%
1Y
-19.9%
Xlife Sciences
Market Cap: CHF 136.9m
Focuses on the development and commercialization of research projects in the life sciences sector.
XLS
CHF 24.00
7D
2.6%
1Y
20.6%
Basilea Pharmaceutica
Market Cap: CHF 617.9m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 49.85
7D
-6.8%
1Y
7.6%